B of A Securities Initiates Coverage On IGM Biosciences with Buy Rating, Announces Price Target of $34
B of A Securities analyst Geoff Meacham initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Buy rating and announces Price Target of $34.